CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. (PubMed, Cell) - Sep 24, 2026 - "Ex vivo treatment of human PDAC specimens with 21h10 induces IFN-γ production by infiltrating T cells. Thus, IL-21-elicited CD4 T cells exert antitumor activity in mice and potentially in humans, converting transient responses to KRAS inhibition into durable remissions."
IO biomarker • Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • CD8 • IFNG • IL21 • KRAS
|
|
Andrew J Aguirre; Birkley S Lim; Brandon M Huffman; Brendan Parent; Brian M Wolpin; Chong Zuo; Corey Perkins; Courtney T S Kureshi; David Baker; Douglas A Rubinson; Eugena Chang; Felix Hambitzer; Frank Peprah; George Molina; Harshabad Singh; Hojeong Shin; James M Cleary; James M Dougan; Jason L Hornick; Jiping Wang; Jonathan A Nowak; Joseph D Mancias; Julissa G Tello; Jung-Ho Chun; Kimberly J Perez; Kwok-Kin Wong; Lauren Brais; Li Qiang; Mark Fairweather; Megan T Hoffman; Michael Dougan; Michael J Walsh; Rakeeb Kureshi; Ritchell van Dams; Sarah Slater; Stephanie K Dougan; Tavus Atajanova; Thomas E Clancy; Yaniris Molina-Aponte
|